Sevirumab

DRUG4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Sandoz

Conditions

Cytomegalovirus InfectionsCytomegalovirus RetinitisHIV Infections

Phase 1

A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria

CompletedNCT00002268

SandozCytomegalovirus Infections, HIV Infections

Updated: 2005-06-24

A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis

CompletedNCT00002016

SandozCytomegalovirus Retinitis, HIV Infections

Updated: 2005-06-24

Phase 2

A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)

CompletedNCT00000836

National Institute of Allergy and Infectious Diseases (NIAID)Cytomegalovirus Retinitis, HIV Infections

End: 1998-08-31Target: 300Updated: 2012-10-25

Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS

CompletedNCT00001061

National Institute of Allergy and Infectious Diseases (NIAID)Cytomegalovirus Retinitis, HIV Infections

End: 1998-03-31Target: 167Updated: 2021-11-01